AVXL stock
Biotech

AVXL Stock Ready To Make A Big Move

AVXL stock was a big winner for us here at Insider Financial back in 2015 when we caught the run from $1 to just over $14. Since then, AVXL stock really hasn’t done much. But now, things are about to change as data was just released on its Phase 2 controlled trial evaluating the safety, tolerability, and efficacy of ANAVEX 2-73 (blarcamesine) in patients with Parkinson’s disease dementia (PDD).

Now there are a couple of interesting takeaways from this data release. For one, the “Night King of Biotech” Adam Feuerstein didn’t Tweet about AVXL stock. In the past, Anavex could have announced that it cured cancer, and the so-called “Night King” would have had some snarky comment to make. His modus operandi has always been spreading FUD about the most-promising small-cap biotechs for his employer Big Pharma.

Second, while AVXL stock did close higher on the day, there was a great deal of selling pressure throughout the trading session. Matter of fact, shares closed at $4.75, below the day’s VWAP of $4.94 a share.

AVXL Stock Daily Chart

The reason for this is that many traders were expecting the data to be released with the PR. However, the plan is for ANAVEX®2-73-PDD-001 study results will be submitted for presentation at a medical conference and for publication in a peer-reviewed medical journal. This is where Dr. Christopher U. Missling will do the great unveiling.

Furthermore, if anyone actually thinks that maybe the data isn’t that good, we have a bridge to sell. The fact is Dr. Christopher U. Missling is not going to go and embarrass himself at a medical conference or in a peer-reviewed medical journal if the data wasn’t phenomenal.

How do we know this?

TWO WORDS – STATISTICALLY SIGNIFICANT

The study found that ANAVEX®2-73 (blarcamesine) was safe and well-tolerated in oral doses up to 50 mg once daily. The results show clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis. The study confirmed the precision medicine approach of targeting SIGMAR1 as a genetic biomarker of response to ANAVEX®2-73 (blarcamesine).

Third, we believe this data sets up AVXL stock to post positive data in the treatment of Rett’s Syndrome in Q4 and more importantly, Alzheimer’s in 2021.

Alzheimer’s is where the big potential lies. We believe ANAVEX 2-73 is the most promising drug being developed right now for Alzheimer’s. ANAVEX 2-73 is based on oxidation and nitration causing Alzheimer’s. Other drug companies have instead focused on the cause being amyloid. They have misdiagnosed the cause while we believe Anavex has the correct approach.

Anti-amyloid and anti-tau drugs have proven to only slightly slow down the progression of Alzheimer’s disease. The prevention or removal of either have shown little effect on the progression of the disease.

Inflammation, tau, and amyloid all add to oxidative stress but are themselves the products of this stress. The key then is not only to inhibit oxidative stress (which only moderately slows down the progression of the disease over time), but to remove compounds that are causing oxidation and nitration, and reverse part of the damage that they are doing to the brain.

Oxidation and nitration also likely play a role in Parkinson’s Disease Dementia and Rett syndrome. This is why we believe Anavex 2-73 is the most promising drug being developed today.

Bottom Line

Traders and investors need to understand that Dr. Christopher U. Missling is playing the long-game with AVXL stock. He’s been doing this for far too long to be concerned about the everyday price gyrations. With the results from PDD being positive, we see a floor now in AVXL stock and one in which investors can build a base off. We are expecting a big move in AVXL stock once data from PDD is released by Dr. Christopher Missling at the medical conference and in the peer-reviewed journal. From there, we will see the excitement build for results in Rett Syndrome, followed by Alzheimer’s. We know it’s been a long road for AVXL shareholders. The payoff is coming, just need to be a little more patient.

As always, good luck to all (except the shorts)!

WHEN INSIDER FINANCIAL HAS A STOCK TIP, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!

Disclosure: We have no position in NASDAQ:AVXL or any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.

Image by Raman Oza from Pixabay

GET NOTIFIED
Sign up for our next MicroCap Runner ahead of the crowd!
We hate spam. No Hidden Fees. Unsubscribe Anytime.
AVXL Stock Ready To Make A Big Move
Click to comment
To Top